FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher S. Dhoot, MD, discusses 52-week phase 1 data for Axpaxli for the treatment of neovascular age-related macular degeneration.
In the trial, patients were randomly assigned to treatment with either Axpaxli (axitinib intravitreal implant, Ocular Therapeutix), also known as OTX-TKI, or aflibercept, with Axpaxli demonstrating “fantastic durability results” in addition to a positive safety profile.
“There was maintenance of visual acuity in OCT parameters in this study as you might